Found 6 results
Author Title [ Type(Desc)] Year
Filters: Author is Weisdorf, DJ  [Clear All Filters]
Journal Article
J. Levine, Logan, B., Wu, J., Alousi, A., Bolanos-Meade, J., Ferrara, J., Ho, V., Weisdorf, D. J., and Paczesny, S., Acute Graft-Versus-Host Disease Biomarkers Measured During Therapy Can Predict Treatment Outcomes: A Blood and Marrow Transplant Clinical Trials Network Study, Blood, vol. 119, pp. 3854-3860, 2012.
J. Bolanos-Meade, Wu, J., Logan, B. R., Levine, J. E., Ho, V. T., Alousi, A. M., Weisdorf, D. J., and Luznik, L., Lymphocyte Phenotype During Therapy for Acute Graft Versus Host Disease: A Brief Report from BMT CTN 0302, Biol Blood Marrow Transplant, vol. 19, pp. 481-485, 2013.
J. Bolanos-Meade, Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., and Ho, V. T., Phase 3 Clinical trial of Steroids/Mycophenolate Mofetil vs Steroids/Placebo as Therapy for Acute GVHD: BMT CTN 0802, Blood, vol. 124, pp. 3221-3227, 2014.
D. J. Weisdorf, Hurd, D., Carter, S., Howe, C., Jensen, L. A., Wagner, J., Stablein, D., Thompson, J., and Kernan, N. A., Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: A grading algorithm versus blinded expert panel review, Biol Blood Marrow Transplant, vol. 9, pp. 512-8, 2003.
D. J. Weisdorf, Hurd, D., Carter, S., Howe, C., Jensen, L. A., Wagner, J., Stablein, D., Thompson, J., and Kernan, N. A., Prospective Grading of Graft-Versus-Host Disease After Unrelated Donor Marrow Transplantation: a Grading Algorithm Versus Blinded Expert Panel Review, Biol Blood Marrow Transplant, vol. 9, no. 8, pp. 512-518, 2002.
G. A. Yanik, Horowitz, M. M., Weisdorf, D. J., Logan, B. R., Ho, V. T., Soiffer, R. J., Carter, S. L., Wu, J., ,, Difronzo, N. L., Ferrara, J. L., Giralt, S., Madtes, D. K., Drexler, R., White, E. S., and Cooke, K. R., Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation: BMT CTN Protocol, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-864, 2014.